“Globally, we continue to see growing interest in the development of oral PCSK9 inhibitors, which clinicians consider to be an optimal approach to LDL-cholesterol lowering as an adjunct to statin treatment.”
Made with FlippingBook
RkJQdWJsaXNoZXIy MjE2NDg3